Clinicopathological profile of male breast cancer: an institutional experience from Western Bihar, India

Binay Kumar; Punya; Abhinav Kumar

doi:10.18203/2320-6012.ijrms20263265

Authors

Binay Kumar Department of Pathology, Netaji Subhas Medical College and Hospital (NSMCH), Bihta, Bihar, India
Punya Department of Pathology, Netaji Subhas Medical College and Hospital (NSMCH), Bihta, Bihar, India
Abhinav Kumar Department of Pathology, Netaji Subhas Medical College and Hospital (NSMCH), Bihta, Bihar, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20263265

Keywords:

Male breast carcinoma, Hospital case accrual, Bihar, Invasive ductal carcinoma, Clinicopathological profile

Abstract

Background: Male breast carcinoma (MBC) is rare (~1% of breast diagnoses) and often presents at advanced stages due to limited awareness, screening guidelines, and medical guidance. Data from Bihar, India, remains scarce. This study assessed institutional accrual alongside demographic, clinical, histological, and stage profiles at Netaji Subhas Medical College and Hospital (NSMCH), Bihta, Patna.

Methods: An ambispective observational cohort study (January 2019 to December 2025) histopathologically confirmed primary male breast cancer (MBC) cases were included (retrospective: 2019–2023; prospective: 2024–2025). Age, symptoms, histological subtype, and AJCC 8th Edition (pTNM) stage were recorded. Data were analyzed using descriptive statistics with exact binomial and Poisson confidence intervals.

Results: Over seven years, 36 patients were identified (mean accrual: 5.14 cases/year), predominantly aged 60–84 years. Painless breast lump was the chief symptom in 28 patients (77.7%). Invasive ductal carcinoma (no special type) was the predominant variant (33 cases, 91.7%). Advanced Stage III or IV disease was present in 27 patients (75.0%) at initial diagnosis.

Conclusions: MBC in western Bihar primarily affects older men and usually presented at advanced stages through symptom-driven detection, dominated by invasive ductal carcinoma. Improving public awareness, screening efficiency, rapid histopathological diagnosis, referral networks, and regional cancer registration is essential.

References

Giordano SH. Breast Cancer in Men. N Engl J Med. 2018;378(24):2311-20.

Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet. 2006;367(9510):595-604.

Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population‐based study. Cancer: Interdisciplinary Int J Am Cancer Soc. 2004;101(1):51-7.

Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2010;28(2):232-9.

Miao H, Verkooijen HM, Chia KS, Bouchardy C, Pukkala E, Larønningen S, et al. Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol. 2011;29(33):4381-6.

Cardoso F, Bartlett JM, Slaets L, Van Deurzen CH, van Leeuwen-Stok E, Porter P, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018;29(2):405-17.

Vermeulen MA, Slaets L, Cardoso F, Giordano SH, Tryfonidis K, van Diest PJ, et al. Pathological characterisation of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Eur J Cancer. 2017;82:219-27.

Piscuoglio S, Ng CK, Murray MP, Guerini-Rocco E, Martelotto LG, Geyer FC, et al. The genomic landscape of male breast cancers. Clin Cancer Res. 2016;22(16):4045-56.

Pritzlaff M, Summerour P, McFarland R, Li S, Reineke P, Dolinsky JS, et al. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Breast Cancer Res Treatment. 2017;161(3):575-86.

Maguire S, Perraki E, Tomczyk K, Jones ME, Fletcher O, Pugh M, et al. Common susceptibility loci for male breast cancer. J Nat Cancer Institute. 2021;113(4):453-61.

Li S, Silvestri V, Leslie G, Rebbeck TR, Neuhausen SL, Hopper JL, et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. J Clin Oncol. 2022;40(14):1529-41.

Swerdlow AJ, Schoemaker MJ, Higgins CD, Wright AF, Jacobs PA. Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Nat Cancer Institute. 2005;97(16):1204-10.

Swerdlow AJ, Bruce C, Cooke R, Coulson P, Griffin J, Butlin A, et al. Obesity and breast cancer risk in men: a national case-control study in England and Wales. JNCI Cancer Spectrum. 2021;5(5):pkab078.

Co M, Lee A, Kwong A. Delayed presentation, diagnosis, and psychosocial aspects of male breast cancer. Cancer Med. 2020;9(10):3305-9.

Muñoz Carrasco R, Álvarez Benito M, Muñoz Gomariz E, Raya Povedano JL, Martínez Paredes M. Mammography and ultrasound in the evaluation of male breast disease. Eur Radiol. 2010;20(12):2797-805.

Healy NA, Parag Y, Wallis MG, Tanner J, Kilburn-Toppin F. Outcomes of male patients attending the symptomatic breast unit: adherence to local and national imaging guidelines and effectiveness of clinical examination and imaging in detecting male breast cancer. Clin Radiol. 2022;77(1):e64-74.

Hassett MJ, Somerfield MR, Baker ER, Cardoso F, Kansal KJ, Kwait DC, et al. Management of male breast cancer: ASCO guideline. J Clin Oncol. 2020;38(16):1849-63.

Yadav S, Karam D, Bin Riaz I, Xie H, Durani U, Duma N, et al. Male breast cancer in the United States: treatment patterns and prognostic factors in the 21st century. Cancer. 2020;126(1):26-36.

Konduri S, Singh M, Bobustuc G, Rovin R, Kassam A. Epidemiology of male breast cancer. The Breast. 2020;54:8-14.

Leone J, Freedman RA, Lin NU, Tolaney SM, Vallejo CT, Leone BA, et al. Tumor subtypes and survival in male breast cancer. Breast Cancer Res Treatment. 2021;188(3):695-702.

Leone J, Hassett MJ, Freedman RA, Tolaney SM, Graham N, Tayob N, et al. Mortality Risks Over 20 years in men with stage I to III hormone receptor–positive breast cancer. JAMA Oncol. 2024;10(4):508-15.

Valentini V, Silvestri V, Bucalo A, Conti G, Karimi M, Di Francesco L, et al. Molecular profiling of male breast cancer by multigene panel testing: implications for precision oncology. Front Oncol. 2023;12:1092201.

Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan KL, Santhappan S, et al. Cancer statistics, 2020: report from national cancer registry programme, India. JCO Glob Oncol. 2020;6:1063-75.

Shah S, Bhattacharyya S, Gupta A, Ghosh A, Basak S. Male breast cancer: a clinicopathologic study of 42 patients in eastern India. Indian J Surg Oncol. 2012;3(3):245-9.

Sundriyal D, Kotwal S, Dawar R, Parthasarathy KM. Male breast cancer in India: series from a cancer research centre. Indian J Surg Oncol. 2015;6(4):384-6.

Gogia A, Raina V, Deo SV, Shukla NK, Mohanti BK. Male breast cancer: A single institute experience. Indian J Cancer. 2015;52(4):526-9.

Ram D, Rajappa SK, Selvakumar VP, Shukla H, Goel A, Kumar R, et al. Male breast cancer: A retrospective review of clinical profile from a tertiary cancer care center of India. South Asian J Cancer. 2017;6(04):141-3.

Khandelwal S, Goel P, Sharma R, Sancheti S, Chaudhary D, Goel A, et al. Presentation and spectrum of male breast cancer in a rural cancer center in a subunit of Tata Memorial Center, India. Indian J Surg Oncol. 2021;12(2):330-4.

Soni A, Verma Y, Chauhan A, Kaur P, Kaushal V, Paul D. Male breast cancer: a 30 year retrospective analysis from a tertiary cancer care centre. eCancer Med Sci. 2023;17:1551.

Potu SR, Gumdal V, Koppaka D, Natti HS, Rapole PS, Syed TA. Clinicopathological Spectrum and Biomarker Profile of Male Breast Cancer: A Retrospective Study from a Tertiary Care Center in South India. J Assoc Phys India. 2026;74(3):56-8.